MedTrace Logo

Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia

NCT00207064 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2011-09-19

No results posted yet for this study

Summary

We want to relate disturbances in first-episode schizophrenic patients in serotonin 5-HT2A receptors, brain structure, brain function, and information processing to each other and to psychopathology. Additionally, we want to examine the influence of 5-HT2A receptor blockade on these disturbances. We expect disturbances in the serotonergic system at baseline to correlate with specific structural and functional changes and with disruption in information processing as measured with psychophysiological and neurocognitive methods - and we expect 5-HT2A receptor blockade to reverse some of the functional and cognitive impairments. We do not expect any effect of treatment on brain structure

Conditions

Interventions

DRUG

quetiapine

flexible doses according to the clinical condition

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Copenhagen University Hospital, Hvidovre

    collaborator OTHER

  • Glostrup University Hospital, Copenhagen

    collaborator OTHER

  • The Danish Medical Research Council

    collaborator OTHER

  • Copenhagen Hospital Corporation

    collaborator OTHER

  • University of Copenhagen

    collaborator OTHER

  • AstraZeneca

    collaborator INDUSTRY

  • Birte Glenthoj

    lead OTHER

Principal Investigators

  • Birte Glenthoj, MD, DMSc. · Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychaitric Center Glostrup, Ndr. Ringvej, DK-2600 Glostrup, Denmark

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00207064 on ClinicalTrials.gov